Juva Life Inc JUVAF

RE:RE:NEWS .......

[Richmond]

Great write up colima...!!!! Very encouraging for once..!!! Let's see where this great JUVA gets to... Loved every bit of NR today. Hope our DOWN days are behind us and JUVA outperforms it's targets... ABOVE AND BEYOND!!!!!!!! Felt very discouraged and disappointed as my entry here is above $2.00............. ----------------'--------------------- Vice President of Chemistry for Juva Life, Sanjeev Gangwar Ph.D. states, Todays milestone announcement notes our first patient enrollment, but we will quickly surpass this with many others joining the study. The work we are undertaking is critical so that consumers, patients, doctors, regulators, and our prospective partners can gain from well controlled scientific studies that employ FDA equivalent standards. The need for new, safe, and evidence-based cannabis products which target un-met medical needs is large. This is clearly evidenced by the recent $7.2 billion acquisition of the makers of Epidiolex, currently the only FDA-approved drug containing CBD which solely addresses seizures in rare diseases like severe forms of epilepsy. We are aiming to address numerous conditions and in so doing hope to build commensurate value. We look forward to announcing additional advances regarding our registry as well as initial plans for our chemistry program in the coming weeks as we continue to accelerate our efforts.

colima wrote:

JUVAF is a vertically integrated medical and recreational cannabis company. Juva Cultivation, Juva Research, Juva Retail, and Juva Delivery are the segments under which it operates. JUVAF ended Friday’s trading session at $1.03, gaining 5.4% over the past year. JUVAF aims to be a pioneer in creating “cannabis therapeutic” data for medical cannabis market in the United States.

The company  started its operations in 2019 and has unique offerings but it is still in its  nascent stages. Hence, there is a lot of ambiguity about its prospects in the near term.

JUVAF’s uncertain prospects are reflected in its POWR Ratings. The stock has an overall rating of C, which equates to Neutral in our proprietary rating system. It has a C for Growth, Stability, and Sentiment. It is ranked #124 in the Medical – Pharmaceuticals industry.

In total, we rate JUVAF on eight different levels. Beyond what we stated above we also have given JUVAF grades for Value, Momentum, and Quality. Get all the JUVAF ratings here.

The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.